Intramuscular injection of a gene therapy known as AMG0001 (Collategene, AnGes Inc.) significantly decreased healing time and increased healing rates of neuroischemic ulcers compared with placebo in patients with chronic limb-threatening ischemia (CLTI) and nonhealing ulcers associated with peripheral artery disease (PAD), a phase 2 trial showed. 

These patients face devastating risks for amputation and mortality in the absence of an FDA-approved therapy to directly promote wound healing, said study co-investigator David Armstrong, MD, distinguished professor of surgery and neurological surgery at the Keck School of Medicine of the University of Southern California, Los Angeles. 

Many of them “live in a therapeutic ‘gray zone’ of being too ischemic to heal, yet not candidates for surgical or endovascular intervention,” he told Medscape Medical News.

Source: MEDspace